Monocinque retard capsules 50mg N30
Condition: New product
996 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Isosorbide mononitrate
Release form
Capsules
Composition
Isosorbide-5-mononitrate 50 mg Auxiliary substances: sucrose, corn starch, ethyl cellulose, stearic acid, talc, dye red 4R (E124), quinoline yellow (E104), titanium dioxide, gelatin. 15 pieces - blisters (2) - cardboard boxes.
Pharmacological effect
Absorption and metabolism: After oral administration, isosorbid-5-mononitrate is rapidly and completely absorbed from the gastrointestinal tract. Bioavailability of the drug when administered is from 90 to 100%. Cmax in blood plasma is achieved in 1-1.5 h after administration. Not affected by first pass through the liver. Excretion: Isosorbide-5-mononitrate is excreted by the kidneys exclusively in the form of metabolites. Approximately 2% is displayed unchanged. T1 / 2 is about 5 hours, which is about 8 times higher than that of isosorbide dinitrate.
Indications
Prevention and long-term treatment of angina III-IV functional classes. Restorative treatment after myocardial infarction. Treatment of chronic heart failure (as part of combination therapy).
Contraindications
Acute circulatory disorders (shock, vascular collapse). Hemorrhagic stroke. Acute stage of myocardial infarction. The simultaneous administration of phosphodiesterase inhibitors (sildenafil). Severe arterial hypotension (systolic hell <90 mm Hg, diastolic hell <60 mm Hg). Condition after traumatic brain injury. Closed angle glaucoma. Deficiency of glucose-6-phosphate dehydrogenase. Age up to 18 years. Hypersensitivity to organic nitrates.
Precautionary measures
On the part of the cardiovascular system: at the beginning of treatment - nitrate headache, which usually decreases after a few days with continued therapy; after the first dose or after increasing the dose - arterial (including orthostatic) hypotension, accompanied by tachycardia, dizziness, weakness. On the part of the digestive system: very rarely - nausea, vomiting.
Use during pregnancy and lactation
In pregnancy, the drug can be prescribed only under strict indications, when the expected therapeutic effect for the mother outweighs the potential risk to the fetus.If there is a need for the drug during lactation, then breastfeeding should be stopped.
Dosage and administration
Monocinque retard prescribed 50 mg (1 capsule.) 1 time / day in the morning after eating, without chewing and washing down with a small amount of liquid. The dose should be adjusted depending on the condition of the patient.
Side effects
When taking Monocinque retard in the recommended dose Side effects are not described. However, as with the use of other nitrates, it is possible: From the side of the cardiovascular system at the beginning of treatment - nitrate headache, which usually decreases after a few days with continued therapy. after the first dose or after increasing the dose - arterial (including orthostatic) hypotension, accompanied by tachycardia, dizziness, weakness. On the part of the digestive system it is very rare - nausea, vomiting. Dermatological reactions are very rare - facial redness and skin allergic reactions.
Overdose
No cases of overdose have been reported. However, when symptoms of overdose occur, generally accepted measures are recommended: induce vomiting, flush the stomach. It is necessary to control whether the patient has taken any other medicines at the same time, to monitor the hemodynamic parameters.
Interaction with other drugs
While taking Monochinkwe retard with other vasodilators, antihypertensive drugs, beta-blockers, calcium channel blockers, antipsychotics, tricyclic antidepressants, sildenafil, ethanol, potentiation of the hypotensive effect of Monocinque retard is possible.
special instructions
The drug is not used for the relief of strokes. For hypertension, the drug is used only under the supervision of a physician. The drug is prescribed both as monotherapy and in combination with beta-blockers, calcium channel blockers, ACE inhibitors, cardiac glycosides or diuretics. Impact on the ability to drive vehicles and control mechanisms: When taking the drug may reduce the ability to concentrate and speed psychomotor reactions, and therefore not recommended driving and other potentially dangerous activities.